Lu Liang
Guangzhou Municipal And Guangdong Provincial Key Laboratory Of Molecular Target & Clinical Pharmacology, The NMPA And State Key Laboratory Of Respiratory Disease
Guangzhou, 511436, China
Guangzhou, 511436, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Acidic-responsive nano liposomes potentiate in situ dual immunotherapy on lung cancer by codelivering antagonistic peptide and agonist.
Journal: International journal of pharmaceutics: X
Published: March 02, 2026
The novel strategy to overcome the drug-resistant lung cancer: Dual targeting delivery of PROTAC to inhibit cancer-associated fibroblasts and lung cancer cells.
Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
Published: September 22, 2025
Bioinspired PROTAC-induced macrophage fate determination alleviates atherosclerosis.
Journal: Acta pharmacologica Sinica
Published: November 16, 2022
Promoter methylation-regulated miR-148a-3p inhibits lung adenocarcinoma (LUAD) progression by targeting MAP3K9.
Journal: Acta pharmacologica Sinica
Published: October 03, 2021
Hybrid artificial cell-mediated epigenetic inhibition in metastatic lung cancer.
Journal: Journal of colloid and interface science
Published: March 08, 2021
Triptolide suppresses the growth and metastasis of non-small cell lung cancer by inhibiting β-catenin-mediated epithelial-mesenchymal transition.
Journal: Acta pharmacologica Sinica
Published: September 04, 2020
MiR-142-3p enhances chemosensitivity of breast cancer cells and inhibits autophagy by targeting HMGB1.
Journal: Acta pharmaceutica Sinica. B
Published: July 24, 2019
CuS Nanodot-Loaded Thermosensitive Hydrogel for Anticancer Photothermal Therapy.
Journal: Molecular pharmaceutics
Published: September 05, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026